| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 2
| Issue : 1 | Page : 6 |
|
|
Management of adverse events post-COVID-19 vaccination with Covaxin and Covishield: A literature review
Ayush Kumar1, Shweta Shrivastava2, Prashant Tiwari3
1 Department of Medicine, TATA MOTORS Hospital, TELCO, Jamshedpur, Jharkhand 831004, India
2 Department of Pharmacology, School of Pharmacy, ARKA JAIN University, Jamshedpur, Jharkhand 832108, India
3 Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore 560078, India
Correspondence Address:
Prashant Tiwari
Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Bangalore 560078
India
 Source of Support: None, Conflict of Interest: None  | 2 |
DOI: 10.4103/2773-0344.347378
|
|
|
Covaxin and Covishield have been granted approval for emergency medical use in India due to the severity of COVID-19. Both vaccines are safe and effective and have a good immunogenic response. There is no difference between Covaxin and Covishield in terms of dosages and both can be administered as 0.5 mL (containing 6 mg of virus antigen for Covaxin and 5×1010 virus particles for Covishield) in the upper arm region. Covaxin and Covishield are designed for a two dose schedule, and it is advised that the second dose of Covaxin be administered 4-6 weeks after the first dose while 12-16 weeks after the first dose for Covishield. These vaccines may have several side effects such as swelling and itching at the injection site, joint pain, dizziness, headache, allergic reaction, increased heartbeat, and fever. Appropriate counselling and suggestion should be provided for any symptoms associated with vaccination so that post-vaccinated issues can be managed. Physician and community pharmacists may play a vital role in the management of adverse drug event associated with vaccines.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
